Oncopeptides AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was SEK 54.28 million. Net loss was SEK 777.55 million compared to SEK 383.36 million a year ago. Basic loss per share from continuing operations was SEK 10.33 compared to SEK 5.71 a year ago. For the nine months, sales was SEK 140.01 million. Net loss was SEK 1,036.33 million compared to SEK 1,081.73 million a year ago. Basic loss per share from continuing operations was SEK 14.27 compared to SEK 17.87 a year ago.